Anchorage dependency is a characteristic that distinguishes normalcy from the cancerous state. In normal cells, adhesion to the extracellular matrix is critical for many processes, including cell proliferation. By contrast, neoplastic cells bypass the requirement for adhesion and proliferate in an adhesion-independent manner. Integrins are the main cellular receptors for the extracellular matrix and acting via Rho family GTPases initiate actin cytoskeletal rearrangements. Our long-term objectives are to understand how integrins regulate cell proliferation and how cancerous cells overcome the requirement for adhesion. Integrins modulate growth factor-initiated signal transduction. The extracellular signal regulated kinase (ERK) cascade is an important growth factor-stimulated pathway. Growth factor-mediated ERK signaling is required for cell cycle progression and we have demonstrated that both activation and nucleocytoplasmic trafficking of ERK are regulated by integrins. Integrin-dependent ERK nucleocytoplasmic trafficking is poorly defined and the proposed experiments will provide important insights into this control. Immunofluorescence and biochemical approaches will be utilized to analyze ERK localization and activity in the nucleus in adhesion-dependent cell models.
Specific Aim 1 will determine the role of ERK import, export and cytoplasmic anchoring in adhesion control of ERK nuclear accumulation.
Specific Aim 2 will test the involvement of Rho family GTPases in ERK nucleocytoplasmic trafficking. Melanoma has the fastest rising cancer incidence rate. ERK activation and nuclear accumulation are adhesion-independent in metastatic melanoma cells. B-Raf is a component of the ERK cascade and is frequently mutated in melanoma. Expression of mutant B-Raf is sufficient to promote adhesion-independent nuclear accumulation of ERK in primary melanocytes.
Specific Aim 3 will establish the contribution of mutant B-Raf-mediated constitutive nuclear accumulation of ERK to melanocyte cell cycle progression in the absence of integrin-mediated adhesion. Fulfillment of these Aims will lead to a mechanistic understanding of integrin control of ERK localization and determine the consequences of constitutive nuclear accumulation of ERK to aberrant cell proliferation. These studies should ultimately lead to novel strategies to target aberrant cell proliferation in melanoma.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM067893-04
Application #
7265200
Study Section
Pathobiochemistry Study Section (PBC)
Program Officer
Flicker, Paula F
Project Start
2004-08-01
Project End
2009-07-31
Budget Start
2007-08-01
Budget End
2008-07-31
Support Year
4
Fiscal Year
2007
Total Cost
$262,173
Indirect Cost
Name
Albany Medical College
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
190592162
City
Albany
State
NY
Country
United States
Zip Code
12208
Ozaki, Shinji; Vuyyuru, Raja; Kageyama, Ken et al. (2016) Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization. Am J Pathol 186:43-56
Shao, Yongping; Le, Kaitlyn; Cheng, Hanyin et al. (2015) NF-?B Regulation of c-FLIP Promotes TNF?-Mediated RAF Inhibitor Resistance in Melanoma. J Invest Dermatol 135:1839-1848
Hartsough, Edward; Shao, Yongping; Aplin, Andrew E (2014) Resistance to RAF inhibitors revisited. J Invest Dermatol 134:319-325
Weiss, Michele B; Abel, Ethan V; Dadpey, Neda et al. (2014) FOXD3 modulates migration through direct transcriptional repression of TWIST1 in melanoma. Mol Cancer Res 12:1314-23
Le, Kaitlyn; Blomain, Erik S; Rodeck, Ulrich et al. (2013) Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res 26:509-17
Abel, Ethan V; Basile, Kevin J; Kugel 3rd, Curtis H et al. (2013) Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest 123:2155-68
Basile, K J; Abel, E V; Aplin, A E (2012) Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene 31:2471-9
Kaplan, Fred M; Kugel 3rd, Curtis H; Dadpey, Neda et al. (2012) SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor. J Biol Chem 287:41797-807
Shao, Y; Aplin, A E (2012) ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity. Cell Death Dis 3:e253
Weiss, Michele B; Abel, Ethan V; Mayberry, Melanie M et al. (2012) TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells. Cancer Res 72:6382-92

Showing the most recent 10 out of 32 publications